首页> 美国卫生研究院文献>Engineering in Life Sciences >Production of polycaprolactone nanoparticles with hydrodynamic diameters below 100 nm
【2h】

Production of polycaprolactone nanoparticles with hydrodynamic diameters below 100 nm

机译:流体动力学直径低于100 nm的聚己内酯纳米颗粒的生产

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Cancer is a worldwide increasing burden and its therapy is often challenging and causes severe side effects in healthy tissue. If drugs are loaded into nanoparticles, side effects can be reduced, and efficiency can be increased via the enhanced permeability and retention effect. This effect is based on the fact that nanoparticles with sizes from 10 to 200 nm can accumulate in tumor tissue due to their leaky vasculature. In this work, we produced polycaprolactone (PCL) in the sizes 1.8, 5.4, and 13.6 kDa and were able to produce spherical shaped nanoparticles with mean diameters of 64 ± 19 nm out of the PCL and 45 ± 8 nm out of the PCL reproducibly. By encapsulation of paclitaxel the diameter of that nanoparticles did not increase, and we were able to encapsulate 73 ± 7 fmol paclitaxel per 1000 particles in the PCL ‐nanoparticles and 35 ± 8 fmol PTX per 1000 PCL ‐nanoparticles. Furthermore, we coupled the aptamer S15 to preformed PCL ‐nanoparticles resulting in particles with a hydrodynamic diameter of 153 nm. This offers the opportunity to use these nanoparticles for targeted drug delivery.
机译:癌症是世界范围内日益增加的负担,其治疗通常具有挑战性,并在健康组织中引起严重的副作用。如果将药物装载到纳米颗粒中,则可以减少副作用,并可以通过增强的渗透性和保留效果来提高效率。此效果基于以下事实:尺寸为10至200 nm的纳米颗粒由于其渗漏的脉管系统会积聚在肿瘤组织中。在这项工作中,我们生产了大小分别为1.8、5.4和13.6 kDa的聚己内酯(PCL),并且能够重现PCL中平均直径为64±19 nm和PCL中平均为45±8 nm的球形纳米颗粒。通过紫杉醇的包封,纳米颗粒的直径没有增加,我们能够在PCL纳米颗粒中每1000粒封装73±7 fmol紫杉醇,每1000个PCL纳米颗粒中封装35±8 fmol PTX。此外,我们将适体S15与预成型的PCL纳米颗粒偶联,产生了流体动力学直径为153 nm的颗粒。这提供了将这些纳米颗粒用于靶向药物递送的机会。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号